GT Biopharma (GTBP) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Theriva Biologics (TOVX) over the past year, gaining 789.5% versus a loss of 55.7%. Over five years, GTBP leads with a -96.3% price change compared with -99.8% for TOVX. GT Biopharma is the larger company by market cap ($12.1 million vs $10.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | TOVX |
|---|---|---|
| Share price | $6.68 | $0.217 |
| Market cap | $12.05M | $9.96M |
| 1-day change | +12.27% | -4.45% |
| YTD return | +750.96% | +3.33% |
| 1-year return | +789.48% | -55.71% |
| 5-year return | -96.32% | -99.80% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-161.13 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $0.86 |
| 52-week low | $4.91 | $0.16 |
| Distance from 52-week high | -76.77% | -74.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +1022.75% | +1052.07% |
| Average volume | 55.52K | 525.96K |
| Shares outstanding | 1.80M | 45.89M |
| Employees | 1 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed TOVX by 845.2 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
GTBP vs TOVX FAQ
Which is bigger, GT Biopharma or Theriva Biologics?
GT Biopharma (GTBP) is larger, with a market capitalization of $12.05M compared with $9.96M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, GTBP or TOVX?
GTBP returned +789.48% over the past 12 months, compared with -55.71% for TOVX (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.